Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis.
- Published In:
- Journal of diabetes investigation, 16(1), 83-92 (2025)
- Authors:
- Gong, Jie, Gao, Fengwei, Jiang, Kangyi, Xie, Qingyun, Zhao, Xin, Lei, Zehua
- Database ID:
- RPEP-11148
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-11148APA
Gong, Jie; Gao, Fengwei; Jiang, Kangyi; Xie, Qingyun; Zhao, Xin; Lei, Zehua. (2025). Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis.. Journal of diabetes investigation, 16(1), 83-92. https://doi.org/10.1111/jdi.14340
MLA
Gong, Jie, et al. "Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis.." Journal of diabetes investigation, 2025. https://doi.org/10.1111/jdi.14340
RethinkPeptides
RethinkPeptides Research Database. "Risk of biliary diseases in patients with type 2 diabetes or..." RPEP-11148. Retrieved from https://rethinkpeptides.com/research/gong-2025-risk-of-biliary-diseases
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.